Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01364922 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Chronic Low Back Pain Study
A Phase 2 study, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 2
- Development phase
- 168
- Enrollment target
NCT01364922 is a Phase 2 study that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 168 participants.
The verdict
NCT01364922, a Phase 2 study, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 168 participants
- Enrollment target
Study Summary
The primary purpose of this study was to evaluate the analgesic effect and safety of hydrocodone/acetaminophen extended release compared to placebo.
Interventions
- DRUG Placebo
- DRUG hydrocodone/acetaminophen extended release
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2011-06 |
| Est. Completion | 2011-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01364922
The ClinicalTrials.gov registry entry for NCT01364922 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 168 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01364922 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01364922 about?
NCT01364922 is a clinical study titled "Phase 2 Chronic Low Back Pain Study". The primary purpose of this study was to evaluate the analgesic effect and safety of hydrocodone/acetaminophen extended release compared to placebo.
What is the current status of trial NCT01364922?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 168 participants. The study started on 2011-06. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01364922?
The interventions under investigation include: Placebo (DRUG), hydrocodone/acetaminophen extended release (DRUG).
Who is sponsoring clinical trial NCT01364922?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.